AU
UK
CA
NZ
IND
US
Guided Therapeutics, Inc.is a medical device company developing non-invasive diagnostic platforms based on biophotonic technology. Its first product, the LuViva® Advanced Cervical Scan, is used for real-time screening of cervical disease at the point of care. Headquartered in the United States, the company collaborates …
HSBC has upgraded Dr Reddy’s Laboratories (NYSE:RDY) American Depositary Receipts (ADRs) fromHoldtoBuy, lifting its price target from USD 14.44 to USD 16.90. The move follows a revised outlook that anticipates a revenue boost from semaglutide, a generic alternative to Novo Nordisk’s high-demand weight-loss and …
Corcept Therapeutics Incorporated (NASDAQ: CORT)is a commercial-stage biopharmaceutical company headquartered in the United States. It focuses on discovering and developing therapies that modulate the effects of cortisol to treat a variety of serious disorders in endocrinology, oncology, metabolism, and neurology.
On June 4, 2025, HC Wainwright & Co. upgraded its rating for Agenus (NasdaqCM: AGEN) fromNeutraltoBuy, reflecting a change in analyst sentiment. The firm’s updated outlook comes as the average one-year price target for the clinical-stage immuno-oncology company rises to USD 6.46 per share, …
On June 4, 2025, HC Wainwright & Co. upgraded AnaptysBio (NasdaqGS:ANAB) fromNeutraltoBuy, signaling a shift in sentiment around the biotechnology company. The change follows updated analyst projections that suggest a significant upside potential based on the current share price.
On Tuesday,Morgan Stanley (NYSE:MS)upgradedKymera Therapeutics (NASDAQ:KYMR)fromEqualweighttoOverweight, raising its price target toUSD79fromUSD49. The move reflects growing interest in the clinical progress of Kymera's drug pipeline, particularly its STAT6-targeting therapy KT-621.
The Ensign Group, Inc. (Nasdaq: ENSG) announced the acquisition of operations at three skilled nursing facilities, adding 232 licensed beds to its portfolio. The acquisitions include Ironwood Rehabilitation and Care Center (80 beds) and Lakeside Rehabilitation and Care Center (100 beds), both located in …
Personalis, Inc. (Nasdaq: PSNL) announced new clinical data from the PREDICT DNA and SCANDARE studies at the ASCO 2025 Annual Meeting, presenting findings that suggest its NeXT Personal™ ctDNA test could serve as a significant prognostic tool for patients with triple negative breast cancer …
Piper Sandler upgraded Claritev Corporation (NYSE: CTEV) toOverweight from Neutralfollowing the company’s Q1 2025 financial results and strategic developments. The firm also increased its price target substantially, from USD 19 to USD 44, reflecting revised expectations for Claritev’s future performance.
InflaRx N.V. (Nasdaq: IFRX) announced that its Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) will be discontinued following a recommendation from the Independent Data Monitoring Committee (IDMC). The IDMC concluded that continuing the trial would be futile based on an unblinded interim …
Please wait processing your request...